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Clinical research in Brazil today can be seen in three dis-
tinct areas. In the first, still acting shy and with few
resources, the research is funded through government
agencies that seek the understanding of some diseases or
peculiar conditions in the country. These include neglected
diseases still endemic in Brazil that do not interest large
international industries. In the second area, funded with
abundant resources coming from international pharmaceu-
tical industries, research studies are carried out to evaluate
the efficacy and safety of drugs in multicenter trials. The
third area, new in the country, is the clinical research of
bioavailability and bioequivalence of drugs that emerged
due to the need for assessing the quality of generic drugs,
which was funded in part with public funds and in part
with funds from national pharmaceutical industries.
Although there are criticisms to all three, they have con-
tributed to boosting clinical research in the country. At the
moment, it is necessary to use a policy to guide their future
directions and coordinate the actions of groups that have
academic competence and are already working traditionally
in the sector, avoiding the opportunism that often takes
place. It is always important to keep in mind that clinical
research is not done only by dilettantism or on behalf of
scientific knowledge. This research involves humans and
therefore it should be conducted in compliance with ethi-
cal principles of autonomy, beneficence, non-maleficence,
justice and equity, concerning the participation of the
research subject and the social relevance of their results. It
should also be considered that the research carried out in
Brazil by major international pharmaceutical conglomer-
ates had the merit of introducing the country to the inter-
national circuit of multicenter clinical research, to
emphasize the quality of our scientists in academia and to
introduce new research protocols. However, neither the
design of these experiment nor the elaboration of protocols
and even the management of the experiments were in
charge of our research groups. When they are not the
responsibility of the industry itself, they are outsourced to
international CROs (Contract Research Organizations),
leaving the Brazilian researcher only in an operational role.
In another scenario we find domestic industries that are
still groping in drug research and development. However,
some have begun to realize the impossibility of surviving in
the market doing just similar and generic drugs. Therefore,
it is necessary that our clinical research is prepared to sup-
port the national pharmaceutical industry that invests in
the development of new drugs, and do so with the same
competence displayed in the quality control of generic
medications. Furthermore, it is of critical importance that
clinical research is also prepared to assist public and private
institutions in obtaining information regarding the diseases
prevalent in the population.
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